Ignite Creation Date:
2025-12-25 @ 12:26 AM
Ignite Modification Date:
2026-01-01 @ 11:48 PM
Study NCT ID:
NCT00355758
Status:
TERMINATED
Last Update Posted:
2010-09-01
First Post:
2006-07-24
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
UCI 03-72 Prostate Cancer Detection by Serum Proteomic Profiling
Sponsor:
University of California, Irvine
Organization:
Study Overview
Official Title:
Prostate Cancer Detection by Serum Proteomic Profiling
Status:
TERMINATED
Status Verified Date:
2010-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Lack of personnel
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
: Researchers would like to see if a new test called SELDI (Surface Enhanced Laser Desorption Ionization) analysis can predict biopsy results better than PSA tests.
Detailed Description:
A blood sample of approximately 30 cc will be collected prior to the patients standard of care radical prostatectomy surgery. This blood will be used for the SELDI analysis. The remainder of the blood sample will be stored and may be used for the PSA test at a later date. The patient will have a final blood draw 3 months to 1 year following surgery.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: